Welcome to our dedicated page for Prenetics Global SEC filings (Ticker: PRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Prenetics Global's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Prenetics Global's regulatory disclosures and financial reporting.
Prenetics Global Ltd (PRE) filed Amendment No. 3 to its Form 20-F for 2025 to revise non-IFRS disclosures and expand explanations of its share of loss from equity-accounted investees and certain non-IFRS metrics, in response to SEC comments. The amendment does not update financial statements or other items beyond these sections.
The filing highlights Prenetics’ pivot into a consumer health and longevity platform anchored by its IM8 brand, which generated $60.1 million of revenue in its first full year and reached $120 million annualized revenue run-rate by December 2025. Total 2025 revenue from continuing operations was $92 million, up sharply from $15 million in 2024, with gross profit of $48 million and a 52.8% margin. The company still recorded a $40 million loss and an adjusted EBITDA loss of $18 million, though Q4 2025 revenue grew to $36.6 million with gross margin improving to about 59%. Prenetics executed divestitures and a $70 million Insighta stake sale, a ~$44 million equity raise, a high-participation warrant exchange, and authorized up to $40 million of share repurchases, while carrying warrant liabilities of $20.3 million at year-end 2025.
Prenetics Global Ltd (PRE) reported that director Hudson Blake Leogrande exercised vested Restricted Stock Units (RSUs) on September 4, 2026. A total of 2,000 RSUs were settled into 2,000 Class A Ordinary Shares at a conversion price of $0.0000 per share under the 2022 Share Incentive Plan. Following the transaction, he held 6,001 Class A Ordinary Shares directly and 18,003 RSUs remained outstanding, each RSU representing a contingent right to one Class A Ordinary Share. No Rule 10b5-1 trading plan is reported.
Prenetics Global Ltd (symbol: PRE) is the issuer of record for a Form 4 filing submitted to the SEC. Tat Thuan Yen reported acquisition or exercise transactions in this Form 4 filing.
Prenetics Global Ltd (PRE) reported that Tat Thuan Yen, VP, Finance of IM8 (US) LLC, received a grant of 10,730 Restricted Stock Units (RSUs) on September 3, 2026 under the company’s 2022 Share Incentive Plan. Each RSU represents one Class A Ordinary Share upon vesting and settlement, subject to continued service.
Prenetics Global Limited (NASDAQ: PRE) reported that CEO Danny Yeung and CFO Brian Rosin purchased a combined $1.0 million of ordinary shares in open-market transactions between August 20 and 25, 2026, following the release of second quarter 2026 results. Leadership has cumulatively invested about $3.75 million in company shares since November 2025, with no sales in that period.
For the second quarter of 2026, Prenetics reported $46.5 million in total revenue, up about 288% year over year, including $45.0 million from IM8, up about 359%. IM8 generated $20.9 million of revenue in July, implying an annualized run-rate of roughly $251 million, and the company recorded its first month of positive consolidated Adjusted Free Cash Flow. Prenetics raised full-year 2026 revenue guidance to $220–$230 million and introduced 2027 revenue guidance of more than $400 million.
Prenetics Global Ltd (PRE) disclosed that Brian J. Rosin, CFO of IM8 (US) LLC, purchased a total of 23,100 Class A Ordinary Shares in open-market or private transactions. He bought 18,000 shares at $21.19 per share on August 24, 2026 and 5,100 shares at $22.80 per share on August 25, 2026. The Rule 10b5-1 checkbox was not marked, indicating these trades were not reported as made under a trading plan.
Prenetics Global Ltd (PRE) reports the initial equity holdings of director Caroline S. Levy. She holds 7,595 Restricted Stock Units (RSUs), each representing a contingent right to receive one Class A ordinary share. These RSUs vest on August 17, 2027, subject to continued service, and expire on August 17, 2033.
Prenetics Global Ltd (symbol PRE) reported that Chief Financial Officer Hoi Chun Lo exercised previously granted Restricted Stock Units (RSUs) into Class A Ordinary Shares on August 21, 2026. He acquired 32,736 Class A Ordinary Shares at $0.0001 per share and 45,815 Class A Ordinary Shares at $0.00 per share through RSU settlements.
The underlying RSU awards were granted under Prenetics Global Ltd's 2022 Share Incentive Plan. Footnotes state that each RSU represents a contingent right to receive one Class A Ordinary Share, that some grants were adjusted following a 1-for-15 reverse stock split, and that vested RSUs are settled in shares at Lo's election in line with the company’s insider trading policy.
Prenetics Global Ltd (PRE) director and CEO Danny Sheng Wu Yeung reported multiple equity transactions. On August 20, 2026 he exercised 53,953 Class A Ordinary Shares from 809,295 Restricted Stock Units at an exercise price of $0.0001 per share equivalent, then transferred 49,912 shares to an ex-spouse pursuant to a domestic relations order. He also purchased a total of 24,681 Class A Ordinary Shares in open-market transactions on August 20 and 24, 2026 at prices between $18.31 and $21.40 per share. The RSUs were granted under the 2022 Share Incentive Plan and were adjusted following a 1-for-15 reverse stock split.
Prenetics Global Limited (NASDAQ: PRE), parent of premium health brand IM8, announced a multi-year global partnership with actress and producer Lily Collins, who becomes IM8’s first film-and-television Global Ambassador and a shareholder in Prenetics. She joins an equity-aligned roster that includes David Beckham, Giannis Antetokounmpo, Aryna Sabalenka, Ollie Bearman, Jay Shetty and Inter Miami CF, and will feature across IM8’s global marketing and product initiatives.
IM8’s flagship Daily Ultimate Essentials has delivered over 57 million servings since its December 2024 launch and currently ships about 200,000 servings per day, with operations in 46 countries and 54% of revenue generated outside the United States. IM8 has reached roughly $251 million in annualized revenue run-rate within 20 months. Driven largely by IM8’s growth, Prenetics raised its full-year 2026 revenue guidance to $220–$230 million and initiated 2027 guidance of $400 million or more. The company achieved positive consolidated Adjusted Free Cash Flow in July 2026 and expects to remain positive for the full third quarter of 2026 and beyond, while expanding its pipeline with IM8 Hydration in Q4 2026 and a premium gummies line in the first half of 2027.
Prenetics Global Limited reported strong growth in its consumer health business for the quarter ended June 30, 2026. Total revenue from continuing operations reached $46.5 million, up 29.3% sequentially and about 3.9x year over year. IM8 contributed $45.0 million, growing 33.2% quarter over quarter and about 4.6x year over year, with IM8 gross margin improving to 65% from 57% a year earlier.
Despite this growth, the company recorded a Q2 net loss of $8.98 million and an Adjusted EBITDA loss of $19.03 million, as acquisition marketing spend rose to $35.7 million. For the first half of 2026, revenue was $82.4 million versus $20.2 million in 2025, while the Adjusted EBITDA loss widened to $24.6 million. July 2026 was the strongest month to date, with revenue of $20.9 million, an IM8 annualized revenue run-rate of roughly $251 million, and the company’s first month of positive consolidated Adjusted Free Cash Flow, which management expects to remain positive from the third quarter onward.
Prenetics closed a $1 billion non-dilutive growth financing facility with General Catalyst’s Customer Value Fund, designed to fund up to 70% of IM8’s marketing spend based on cohort performance. The company raised full-year 2026 guidance to $220–230 million in total revenue, with IM8 expected to generate $215–222 million, and initiated 2027 IM8 revenue guidance of at least $400 million. The balance sheet showed $59.1 million in cash and $50.3 million in current financial assets with no borrowings, following divestitures of ACT Genomics, Europa and Insighta to focus on IM8 and CircleDNA.